Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin.

Wexler LH, Andrich MP, Venzon D, Berg SL, Weaver-McClure L, Chen CC, Dilsizian V, Avila N, Jarosinski P, Balis FM, Poplack DG, Horowitz ME.

J Clin Oncol. 1996 Feb;14(2):362-72.

PMID:
8636745
2.

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.

Speyer JL, Green MD, Zeleniuch-Jacquotte A, Wernz JC, Rey M, Sanger J, Kramer E, Ferrans V, Hochster H, Meyers M, et al.

J Clin Oncol. 1992 Jan;10(1):117-27. Erratum in: J Clin Oncol 1992 May;10(5):867.

PMID:
1727913
3.

Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas.

Lopez M, Vici P, Di Lauro K, Conti F, Paoletti G, Ferraironi A, Sciuto R, Giannarelli D, Maini CL.

J Clin Oncol. 1998 Jan;16(1):86-92.

PMID:
9440727
5.

Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up.

Elbl L, Hrstkova H, Tomaskova I, Michalek J.

Support Care Cancer. 2006 Feb;14(2):128-36.

PMID:
16034614
6.

Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer.

Speyer JL, Green MD, Kramer E, Rey M, Sanger J, Ward C, Dubin N, Ferrans V, Stecy P, Zeleniuch-Jacquotte A, et al.

N Engl J Med. 1988 Sep 22;319(12):745-52.

PMID:
3137469
7.

Cardioprotection with ICRF-187 (Cardioxane) in patients with advanced breast cancer having cardiac risk factors for doxorubicin cardiotoxicity, treated with the FDC regimen.

Jelić S, Radulović S, Nesković-Konstantinović Z, Kreacić M, Ristović Z, Bosnjak S, Milanović N, Vuletić L.

Support Care Cancer. 1995 May;3(3):176-82.

PMID:
7655778
9.

Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.

Venturini M, Michelotti A, Del Mastro L, Gallo L, Carnino F, Garrone O, Tibaldi C, Molea N, Bellina RC, Pronzato P, Cyrus P, Vinke J, Testore F, Guelfi M, Lionetto R, Bruzzi P, Conte PF, Rosso R.

J Clin Oncol. 1996 Dec;14(12):3112-20.

PMID:
8955656
10.
11.

Cardioprotection by dexrazoxane (Cardioxane; ICRF 187): progress in supportive care.

Hellmann K.

Support Care Cancer. 1996 Jul;4(4):305-7. Review.

PMID:
8829310
12.

A phase II trial of cardioprotection with Cardioxane (ICRF-187) in patients with advanced breast cancer receiving 5-fluorouracil, doxorubicin and cyclophosphamide.

Kolaric K, Bradamante V, Cervek J, Cieslinska A, Cisarz-Filipcak E, Denisov LE, Donat D, Drosik K, Gershanovic M, Hudziec P, et al.

Oncology. 1995 May-Jun;52(3):251-5.

PMID:
7715910
13.
14.

Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.

Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL, Barry EV, Asselin BL, Athale U, Clavell LA, Larsen E, Moghrabi A, Samson Y, Michon B, Schorin MA, Cohen HJ, Neuberg DS, Orav EJ, Colan SD.

Lancet Oncol. 2010 Oct;11(10):950-61. doi: 10.1016/S1470-2045(10)70204-7.

15.

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, Jones SE, Wadler S, Desai A, Vogel C, Speyer J, Mittelman A, Reddy S, Pendergrass K, Velez-Garcia E, Ewer MS, Bianchine JR, Gams RA.

J Clin Oncol. 1997 Apr;15(4):1318-32.

PMID:
9193323
16.

Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.

Chow WA, Synold TW, Tetef ML, Longmate J, Frankel P, Lawrence J, Al-Khadimi Z, Leong L, Lim D, Margolin K, Morgan RJ Jr, Raschko J, Shibata S, Somlo G, Twardowski P, Yen Y, Doroshow JH.

Cancer Chemother Pharmacol. 2004 Sep;54(3):241-8.

PMID:
15173955
17.

Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines.

Herman EH, Zhang J, Hasinoff BB, Chadwick DP, Clark JR Jr, Ferrans VJ.

Cancer Chemother Pharmacol. 1997;40(5):400-8.

PMID:
9272116
18.

Use of ICRF-187 for prevention of anthracycline cardiotoxicity in children: preliminary results.

Schiavetti A, Castello MA, Versacci P, Varrasso G, Padula A, Ventriglia F, Werner B, Colloridi V.

Pediatr Hematol Oncol. 1997 May-Jun;14(3):213-22.

PMID:
9185206
19.

A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.

Amadori D, Frassineti GL, Zoli W, Milandri C, Tienghi A, Ravaioli A, Gentile A, Salzano E.

Semin Oncol. 1996 Oct;23(5 Suppl 11):16-22.

PMID:
8893894
20.

[The role of cardioxane (ICRF-187) in the prevention of cardiotoxicity of anthracyclines in the combined drug therapy of extensive ovarian cancer].

Protasov DA, Zel'dovich DR, Kuz'mina LP, Manikhas GM.

Vopr Onkol. 1998;44(6):718-21. Russian.

PMID:
10087973

Supplemental Content

Support Center